Trial Profile
A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Belinostat (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 24 May 2018 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2017 Status changed from suspended to active, no longer recruiting.
- 01 Sep 2017 Status changed from recruiting to suspended.